FIELD: medicine.
SUBSTANCE: there are disclosed new completely human VAP-1 binding antibodies containing three polypeptides CDR of heavy and light chains, and their VAP-1-binding fragments. There are also presented nucleic acids coding VAP-1 antibodies or their fragments, expression vectors and host cells including these nucleic acids for recombinant expression of VAP-1 antibodies. There is described a method for producing a completely human antibody by transformation of the proper host by the expression vector and cultivation with the antibodies to be collected and purified. There are also disclosed pharmaceutical compositions containing said antibodies, and their therapeutic application - for treating VAP-1-mediated inflammatory diseases in the patients.
EFFECT: method improvement.
21 cl, 20 dwg, 4 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF VAP-1 INHIBITORS FOR FIBROTIC SICKNESS TREATMENT | 2010 |
|
RU2580626C2 |
| VAP-1 INHIBITORS ADMINISTRATION FOR FIBROID DISEASES TREATMENT | 2010 |
|
RU2667963C1 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
| RECOVERED IP-10 ANTIBODY, IMMUNOCONJUGATE AND BIOSPECIFIC MOLECULE THEREOF, COMPOSITIONS THEREOF, METHOD OF TREATING (VERSIONS), CODING MOLECULE OF NUCLEIC ACID, RELATIVE EXPRESSION VECTOR, HOST CELL AND HYBRIDOMA | 2004 |
|
RU2486199C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
| ANTIBODIES TARGETING A RECEPTOR BOUND TO G-PROTEINS, AND METHODS FOR USE THEREOF | 2015 |
|
RU2725819C2 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
| RECOVERED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT (VERSIONS), METHOD OF TREATING hTNFα-MEDIATED DISEASES WITH MEDIATION THEREOF (VERSIONS), PHARMACEUTICAL COMPOSITION, RECOMBINANT HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, RECOVERED NUCLEIC ACID (VERSIONS) | 2005 |
|
RU2458704C9 |
